N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART

European Journal of Medical Research

Volumn 12, Issue 4, 2007, Pages 152-160

  Berg, T ^a   Zdunek, D ^c   Stalke, J ^b   Dupke, S ^d   Baumgarten, A ^d   Carganico, A ^d   Hess, Georg ^c  

^a Medizinisches Labor Dr Berg   (Germany)

^b Kardiologisch angiologische Praxis im Spreebogen   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d HIV Schwerpunktpraxis   (Germany)

Author keywords

Cardiac dysfunction; Cardiovascular diseases; Heart failure; Hepatitis C virus; Highly active anti retroviral therapy; Human immunodeficiency virus; N terminal pro B type natriuretic peptide; Natriuretic peptides

Indexed keywords

ABACAVIR; ALPHA INTERFERON; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; C REACTIVE PROTEIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; GW 908; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE DETERMINATION; ARTICLE; BLOOD DONOR; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROIMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SMOKING; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RISK FACTORS;

EID: 34248549409     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Sepkovitz K. AIDS-the first 20 years. N Engl J Med 2001; 344:1764-1772.
2. Casau CN. Prespective on HIV infection and aging. Emerging research on the horizon. Clinical Infectious Disease 2005;41:855-63.
3. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, Pedersen F. The influence of age, sex and othervariables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89(7):745-51.
4. Corless IB, Kenn MK, Kemppainen J, Nicholas PK, McGibbon C, Davis SM, Dolan S. Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care and STD's 2005; 19(9):577-586.
5. Vernochet C, Azoulay S, Duval D, Guedj R, Cottrez F, Vidal H et al. Human Immunodeficiency Virus Protease Inhibitors Accumulate into Cultured Human Adipocytes and Alter Expression of Adipocytokines. J Biol Chem 2005;Vol.280 No.3: 2238-2243.
6. Mehta N, Muredach R. Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. HIV Clin Trials 2005;6(1):5-24.
7. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349 (21): 1993-2003.
8. Baliga RS, Chaves AA, Jing L, Ayers LW, Bauer JA. AIDS related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. AJP-Heart Circ Physiol 2005; 289:H1373-H1380.
9. Vanderheyden M, Bartunek M, Claeys G, Manoharan G, Beckers JF, Ide L. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction. Clin Biochem 2006;39(6):640-5.
10. Kostaka K, Popelova J, Tiserova M, Telekes P, Vrzanova M, Bronsky J, Halacova M, Kukacka J, Prusa R. NT-proBNP and BNP values in cardiac patients with different degree of left ventricular systolic dysfunction. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006;150(1):125-30.
11. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90(3):297-303.
12. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. European J Heart Failure 2004;6:257-260.
13. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur J Heart Fail 2003;24:1710-1718.
14. Arshad A, Bansal A, Patel RC. Cardiac complications of Human Immunodeficiency Virus infection: Diagnostic and therapeutic considerations. Heart Disease 2000;2: 133-145.
15. Barbaro G. Cardiovascular Manifestations of HIV Infection. Circulation 2002;106:1420-1425.
16. Berggren R, Batuman V. HIV-associated Renal Disorders: Recent insights into pathogenesis and treatment. HIV/AIDS Reports 2005;2:109-115.
17. Hess G, Runkel S, Zdunek D, Hitzler WE. Reference interval determination of N-terminal-B-type natriuretic peptide (NT-proBNP): A study in blood donors. Clin Chim Acta 2005;360:187-193.
18. Richtlinien zur Gewinnung von Blut and Blutbestandteilen und zur Anwendung von Blutprodukten(Hämotherapie). Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2000(43);555-589.
19. Olson MH, Hansen TW, Christensen MK, Gustafson F, Rasmussen S, Wachtell K, Borch Johnson K, Ibsen H, Jorgensen T, Hildebrandt P. N-Terminal Pro Brain Peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005; 46(4):660-6.
20. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J et al. N-terminal pro-B-type natriuretic peptide and long term mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
21. Olson MH, Wachtell K, Tuxen C, Fossum E, Bang L, Hall C et al. N-terminal pro brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy. A LIFE study. J Hypertension 2004;22(8):1597-1604.
22. Maisel AS, McCord J, Nowack RM, Hollander JE, Wu AH, Duc P, et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41:2010-7.
23. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48(1):156-63.
24. Stein JH. Managing cardiovascular risk in patients with HIV infection. J Acuir Immune Defic Syndr 2005; 38(2):115-123.
25. Glesby MJ. Coronary Heart Disease in HIV-infected patients. HIV/AIDS Reports 2005;2:68-73.
26. Umeh OC, Currier JS. Lipids, Metabolic Syndrome and Risk factors for future cardiovascular disease among HIV-infected patients. HIV/AIDS Reports 2005;2:132-139.
27. Cotter BR. Endothelial Dysfunction in HIV Infection. HIV/AIDS Reports 2006, 3:126-131.
28. Sevastianova K, Sutinen J, Westerbacka J, Ristola M, Yki-Järvinen H. Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy. Antiviral Therapy 10:925-935.
29. Erlandsen EJ; Randers E. Reference interval for serum C-reactive protein in healthy blood donors using the Dade Behring N Latex CRP mono assay. Scand J Clin Lab Invest 2000;60(1):37-43.
30. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004;109(Suppl IV):IV6-IV19.
31. Mar M, Bernal E, Padilla S, Graells ML, Jarrin I, Almenar MV, Molina J, Hernandez I, Gutierrez F. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2006.
32. Grinspoon SK. Metabolic Syndrome and Cardiovascular Diseases in patients with Human Immunodeficiency Virus. Am J Med 2005;118 suppl 2: 235-285.
33. Shikuma CM, Day LJ, Gerschenson M. Insuline resistance in the HIV-infected population: The potential role of mitochondrial dysfunction. Current Drug Targets-Infectious Disorders 2005;5:255-262.
34. Nolan D, Mallal S. Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sexual Health 2005;2:153-163.
35. Kovacic JC, Martin A, Carey D, Wand H, Mallon P, Feneley MP, Emery S, Cooper DA, Carr A. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk HIV-infected patients with lipoatrophy. Antiviral Therapy 2005;10:135-143.
36. Grinspoon S, Carr A. Medical Progress: Cardiovascular Risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352(1):48-62.
37. Mehta N, Muredach R. Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. HIV Clin Trials 2005;6(1):5-24.
38. Breuckmann F, Neumann T, Kondratieva J, Wieneke H, Ross B, Nassenstein K, et al. Dilated Cardiomyopathy in Two Adult Human ImmunodefiCiency Positive (HIV+) Patients Possibly Related To Highly Active Antiretroviral Therapy (HAART). Eur J Med Res 2005;10:395-399.
39. Carrillo-Jimenez R, Lamas GA, Hennekens CH. Plasma levels of brain natriuretic peptide: A potential marker for HIV-related cardiomyopathy. J Cardiovasc Pharmacol Therapeut 2002;7(3):135-137.
40. Lewis W, Haase CP, Raidel SM, Russ RB, Sutcliff RL, Hoit BD, Samarel AM. Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Laboratory Investigation 2001; 81 (11):1527-1536.
41. Ghio S, DiMatteo A, Scelsi L, Klersy C, Orsolini P, Monti L, Campana C, Minoli L, Tavazzi L. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. European Heart Journal Supplements 2004; 6 (supplement F) F35-F39.
42. Horacek JM, Pudil R, Tichy M, Jebavy L, Strasova A, Praus R, Zak P, Maly J. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005;52(5):430-4.
43. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005;51(8):1405-10.
44. Germanikis I, Kalmanti M, Parthenakis F, Nikitovic D, Stiakaki E, Patrianakos A, Vardas PE. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int J Cardiol 2006;108(2):212-5.
45. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and Heart Failure associated with Hepatitis C Virus Infection. J Card Fail 2006;12 (4):293-298.
46. Bojunga J, Sarrazin C, Hess G, Zeuzem S. Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy. World J Gastroenterology 2006;12(36): 5875-7.
47. Henriksen JH, Goetze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. GUT 2003;52: 1511-7.